Über uns
Unser Angebot
Kontakt
Anmelden
Firmen/WKN-Suche
Suchen
Index
DAX
MDAX
SDAX
TecDAX
9 Neue Einträge heute 755722 Gesamteinträge
HELLA GmbH & Co. KGaA: Tagesordnung zur ordentlichen Hauptversammlung am 26.04.24
Deutsche Post AG: Tagesordnung zur ordentlichen Hauptversammlung am 03.05.24
Deutsche Post AG: ordentliche Hauptversammlung am 02.05.2025 in
Exasol AG: ordentliche Hauptversammlung am 20.06.2024 in
Medios AG: 18.03.24 Medios erwirbt niederländischen Marktführer für pharmazeutische Compounding-Dienstleistungen
Vivoryon Therapeutics AG
Stammdaten
Geschäftsbericht-Bestellung
E-Mail-Service
HV-Termine
(7)
HV-Tagesordnungen
(7)
HV-Beschlüsse
(5)
Satzung
(4)
Kapitalerhöhung
(1)
Berichte
Geschäftsberichte
(8)
Quartalsberichte
(11)
Prospekte
Börsengang
(1)
Unternehmensmeldungen
Mitteilungen des Unternehmens
(50)
Vivoryon Therapeutics AG
Straße
Weinbergweg 22
Adresse
D- 06120 Halle an der Saale
Bundesland
Sachsen-Anhalt
WKN
792183
Telefon
0345-555-9900
Fax
0345-555-9901
Email
contact@vivoryon.com
Homepage
http://www.vivoryon.com
Meldung des Unternehmens
2020
16.12.20 Vivoryon Therapeutics N.V. new Home Member State
30.11.20 Vivoryon Therapeutics AG Announces Conversion into Vivoryon Therapeutics N.V.
26.11.20 Vivoryon Therapeutics Reports Third Quarter 2020
19.11.20 Vivoryon Therapeutics AG to Publish its Third Quarter 2020 Business Update on November 26, 2020
01.10.20 Ordinary General Meeting of Shareholders of Vivoryon Therapeutics AG
03.09.20 Vivoryon Therapeutics Announces Notice of its Ordinary General Meeting of Shareholders to be Held on September 30, 2020
27.08.20 Vivoryon Therapeutics AG plans conversion into Naamloze Vennootschap (N.V.) under Dutch law
27.08.20 Vivoryon Therapeutics AG Reports Financial Results for H1 2020 and Provides Corporate Update
20.08.20 Vivoryon Therapeutics AG to Publish its Half Year 2020 Results on August 27, 2020
04.08.20 Vivoryon Receives IND Approval for Varoglutamstat's (PQ912) Phase 2 Study in Alzheimer's Disease
15.07.20 Vivoryon Therapeutics Announces Enrollment of First Patient in VIVIAD, European Phase 2b Alzheimer's Disease Study with Varoglutamstat (PQ912)
26.06.20 Vivoryon Therapeutics Provides Update on US and EU Alzheimer's Clinical Trial Program with PQ912
14.05.20 Vivoryon Therapeutics AG Reports First Quarter 2020
12.05.20 Vivoryon Therapeutics AG Postpones Annual General Meeting
07.05.20 Vivoryon Therapeutics AG to Publish its First Quarter 2020 Business Update on May 14, 2020
29.04.20 Vivoryon Therapeutics Announces Outcome of Exclusive Option Deal with MorphoSys
16.04.20 Vivoryon Therapeutics Starts Development Program for Meprin Protease Inhibitors with Intended Therapeutic Use in Fibrosis, Cancer and Alzheimer's Disease
26.03.20 Correction of a release from 26/03/2020, 07:00 CET/CEST - Vivoryon Therapeutics AG: Vivoryon Therapeutics AG Reports Full Year 2019 Financial Results
26.03.20 Vivoryon Therapeutics AG Reports Full Year 2019 Financial Results
19.03.20 Vivoryon Therapeutics AG to Publish its Full Year 2019 Results on March 26, 2020
17.03.20 Vivoryon Therapeutics Announces Update on Phase 2b Alzheimer's Clinical Trial, VIVIAD
03.03.20 Vivoryon Therapeutics to Attend Upcoming Investor Conferences
14.01.20 Vivoryon Therapeutics and Nordic Bioscience Enter Research and Development Collaboration
07.01.20 Vivoryon Therapeutics to Attend 38th Annual J.P. Morgan Healthcare Conference in January 2020
2019
20.12.19 Vivoryon Therapeutics is Included in AScX Index
28.11.19 Vivoryon Therapeutics Reports Third Quarter 2019
27.11.19 Vivoryon Therapeutics attends CTAD 2019
21.11.19 Vivoryon Therapeutics AG to Publish Third Quarter 2019 Results on November 28, 2019
24.10.19 Vivoryon Therapeutics AG Successfully Completes a EUR 43 Million Capital Raise
08.10.19 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE WOULD BE UNLAWFUL.
29.08.19 Vivoryon Therapeutics Reports Financial Results for H1 2019 and Corporate Update
22.08.19 Vivoryon Therapeutics AG to Publish its Half Year 2019 Results on August 29, 2019
08.07.19 MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology
27.06.19 Vivoryon Therapeutics AG enters myeloid immune checkpoint drug discovery, and collaborates with the University of Kiel to select cancer therapy candidates from its QPCTL inhibitor portfolio
18.06.19 Vivoryon Therapeutics mandates goetzpartners as strategic business development advisor for expansion of its innovative QPCTL technology into immuno-oncology
12.06.19 Aus Probiodrug AG wird Vivoryon Therapeutics AG
29.05.19 Ordinary General Meeting of Shareholders of Probiodrug AG
16.05.19 Probiodrug Reports First Quarter 2019 Business Update
09.05.19 Probiodrug AG to Publish its First Quarter 2019 Business Update on May 16, 2019
18.04.19 Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 29 May 2019
15.04.19 Probiodrug raises EUR 8.2 million in successful private placement of new shares
09.04.19 Probiodrug raises EUR 8.2 million from investors in successful private placement of new shares
04.04.19 Probiodrug AG has mandated ODDO SEYDLER BANK AG as Designated Sponsor
28.03.19 Probiodrug reports full year 2018 financial results
21.03.19 Probiodrug AG to Publish its Full Year 2018 Results on March 28, 2019
20.03.19 Probiodrug and Alzheimer's Disease Cooperative Study (ADCS) Receive 15 Million USD National Institutes of Health (NIH) Grant for U.S. Phase 2b Core Program for PQ912
2018
18.12.18 Probiodrug to attend J.P. Morgan Healthcare Conference in January 2019
28.11.18 Probiodrug veröffentlicht Quartalsbericht für das dritte Quartal 2018
04.09.18 Probiodrug ernennt Dr. Michael Schaeffer zum Executive Vice President Business & Strategy
29.08.18 Probiodrug berichtet Finanzergebnisse für das erste Halbjahr 2018 und Unternehmens-Update
Tagesordnungen
HELLA GmbH & Co. KGaA
Deutsche Post AG
Münchener Rückversicherungs-Gesellschaft AG
Schwälbchen Molkerei Jakob Berz AG
Merck KGaA
Gegenanträge
Fonterelli GmbH & Co KGaA
Fonterelli GmbH & Co KGaA
Siemens Energy AG
MARNA Beteiligungen AG
Infineon Technologies AG
HV-Beschlüsse
SCHOTT Pharma AG & Co. KGaA
DATAGROUP SE
All for One Group AG
BRAIN Biotech AG
MVV Energie AG